- About
- PsychU For You
- Topics
- Events
- Content
Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Long-Acting Injectables For The Treatment Of Bipolar I Disorder: Relevant Questions From Providers
Join us for this lively discussion with Dr. Joseph Goldberg and Dr. Mauricio Tohen regarding long-acting injectables (LAIs) in the treatment of bipolar I disorder. This moderated session will explore perception, preferences, challenges, and treatment goals for both patients and providers. Discussants will review provider and patient centric perspectives in selecting therapy, plus potential strategies to assess preferences regarding new preventative treatments such as mode of administration, dosing regimen and treatment-related determinants of adherence.
Objectives:- Describe the challenges to long-term treatment and the importance of management options in patients diagnosed with Bipolar I Disorder (BP-I)
- Discuss the pros and cons of LAIs for patients living with BP-I, from the provider and patient perspective
- Understand strategies to aid in shared decision making between providers and patients when considering LAIs
Joseph Goldberg, MD
Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai
MoreDr. Goldberg currently serves as the Clinical Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and serves on the Board of Directors for the American Society of Clinical Psychopharmacology. Dr. Goldberg has published over 200 peer-reviewed papers on topics related to the treatment and clinical features of bipolar disorder, as well as three books on bipolar disorder and psychopharmacology.
Mauricio Tohen, MD, DrPH, MBA
Chairman, Department of Psychiatry, University Distinguished Professor, University of New Mexico Health Science Center
MoreMauricio Tohen, MD, DrPH, MBA, is a University Distinguished Professor and Chairman of the Department of Psychiatry at the University of New Mexico Health Science Center, Albuquerque NM. From 2009 to 2013 he was a Professor of Psychiatry and The Krus Endowed Chair in Psychiatry at the University of Texas Health Science Center at San Antonio. Dr. Tohen received his medical degree from the National University of Mexico and his Doctor of Public Health degree in Epidemiology from Harvard University. His postdoctoral training included a residency in Psychiatry at the University of Toronto, a clinical fellowship at McLean Hospital and Harvard Medical School, and a teaching fellowship in Epidemiology at the Harvard School of Public Health. From 1988 to 1997, Dr. Tohen was the Clinical Director of the Bipolar and Psychotic Disorders Program at McLean Hospital. From 1997 to 2008 he was a member of Lilly Research Laboratories reaching the senior-most scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as the Head of the Division of Mood and Anxiety Disorders. Dr. Tohen received a National Service Award in Psychiatric Epidemiology from the National Institute of Mental Health (NIMH) and Harvard University. He also received a FIRST award from the NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award and the Simon Bolivar Award from the American Psychiatric Association. In 2014 he was named by Thomson Reuter’s “The World’s Most Influential Scientific Minds, 2014”. Honorees were the scientists who ranked in the Top 1 percent by citations of their published work in 21 broad fields between 2002 and 2012.
Michael Aldape, PhD (OPDC)
Senior Medical Science Liaison
Joseph Goldberg, MD and Mauricio Tohen, MD, DrPH, MBA are paid consultants of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)
Michael Aldape, PhD is a paid employee of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)Disclaimer: PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). Specific PsychU programs may be supported by OPDC, OAPI and other committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsor or the sponsors of the specific PsychU program in which such opinions are expressed. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU’s educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC and OAPI.
US.CORP.X.23.00219Related Events
Registration
- PsychU For You
